Quotient (NASDAQ:QTNT) Stock Rating Upgraded by ValuEngine
Separately, BidaskClub upgraded Quotient from a strong sell rating to a sell rating in a report on Friday.
Shares of QTNT stock traded up $0.54 on Friday, reaching $8.47. 880,035 shares of the stock were exchanged, compared to its average volume of 239,319. The stock has a market cap of $525.52 million, a P/E ratio of -4.41 and a beta of 0.99. The company has a quick ratio of 4.42, a current ratio of 5.17 and a debt-to-equity ratio of 72.27. The firm has a 50 day moving average of $8.15 and a two-hundred day moving average of $9.12. Quotient has a 1-year low of $5.52 and a 1-year high of $11.30.
In related news, insider Roland Boyd sold 21,100 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $10.95, for a total value of $231,045.00. Following the completion of the sale, the insider now directly owns 62,508 shares in the company, valued at approximately $684,462.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 14.20% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in QTNT. Clearbridge Investments LLC grew its stake in shares of Quotient by 2.8% during the first quarter. Clearbridge Investments LLC now owns 2,456,616 shares of the company’s stock valued at $22,134,000 after acquiring an additional 67,290 shares in the last quarter. Athanor Capital LP acquired a new stake in shares of Quotient during the second quarter valued at about $182,000. FNY Investment Advisers LLC acquired a new stake in shares of Quotient during the second quarter valued at about $195,000. JPMorgan Chase & Co. grew its stake in shares of Quotient by 10.6% during the second quarter. JPMorgan Chase & Co. now owns 307,578 shares of the company’s stock valued at $2,907,000 after acquiring an additional 29,386 shares in the last quarter. Finally, Rehmann Capital Advisory Group grew its stake in shares of Quotient by 145.4% during the second quarter. Rehmann Capital Advisory Group now owns 41,880 shares of the company’s stock valued at $392,000 after acquiring an additional 24,812 shares in the last quarter. Hedge funds and other institutional investors own 70.56% of the company’s stock.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Featured Story: What Does Beta Mean In Stock Selection?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.